Advances in antithrombin therapy for ST-elevation myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Thrombin plays a critical role in acute myocardial infarction (MI) due to its procoagulant and prothrombotic effects.
• Antithrombin therapy is essential in managing acute MI, with unfractionated heparin (UFH) being the standard agent.
• UFH has limitations including variable efficacy, inability to inhibit clot-bound thrombin, and potential for thrombocytopenia.

Purpose of the Study:

• To review novel antithrombin agents developed to overcome the limitations of UFH in acute MI.
• To evaluate the efficacy and pharmacokinetic advantages of direct thrombin inhibitors and low-molecular-weight heparins (LMWHs).

Main Methods:

• Review of clinical data and pharmacokinetic profiles of novel antithrombin agents.
• Comparison of direct thrombin inhibitors (hirudin, bivalirudin) and LMWHs against UFH in acute MI settings.
• Assessment of antithrombin agents as adjuncts to fibrinolytic therapy in ST-elevation MI (STEMI).

Main Results:

• Direct thrombin inhibitors like hirudin offer marginal benefits, while bivalirudin shows potential in reducing reinfarction.
• LMWHs demonstrate superior pharmacokinetic properties (availability, half-life, dose-independent clearance) and inhibit both thrombin generation and activity.
• LMWHs exhibit a favorable benefit/risk profile when used with various fibrinolytic agents.

Conclusions:

• Novel antithrombin agents represent significant advancements in acute MI pharmacotherapy.
• LMWHs present an attractive alternative to UFH due to their pharmacokinetic advantages and efficacy.
• Further large-scale clinical trials are warranted to establish LMWHs as the preferred antithrombin agent for STEMI.